surepath liquid-based medium (Becton Dickinson)
90
Structured Review
Becton Dickinson
surepath liquid-based medium
Surepath Liquid Based Medium, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/surepath/surepath+medium/10__2807_slash_1560___7917__es__2025__30__27__2400820-90-0-4
Average 90 stars, based on 1 article reviews
Surepath Liquid Based Medium, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/surepath/surepath+medium/10__2807_slash_1560___7917__es__2025__30__27__2400820-90-0-4
Average 90 stars, based on 1 article reviews
surepath liquid-based medium - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
Staining:Article Title: Clinicopathologic Features and Cytologic Correlation of ALK-Rearranged Papillary Thyroid Carcinoma: A Series of Eight Cases. Article Snippet: .. The preoperative FNA specimens were prepared either by conventional or other:Article Title: Evolution of Pathological Techniques for the Screening of Cervical Cancer: A Comprehensive Review Article Snippet: To date, two major LBC preparations have been approved by the FDA: ThinPrep (Cytyc Corporation, Boxborough, Massachusetts, US) in 1996, as an alternative to cervicovaginal smears in the US, followed by Article Title: Advances in diagnostic liquid-based cytology. Article Snippet: The first observation of human cell specimens, known as cytopathology, was made by Johannes Müller (1801–1858) in Germany and it was described in the ‘The first cytopathologist’.1 Contemporary cytopathology plays a crucial role in the screening for cervical dyskaryosis and the diagnosis of cervical cancer, and the establishment of current stable diagnostic methods is attributed to the contributions of several cytopathologists and cytotechnologists, including Dr. George Papanicolaou and other researchers.2,3 In response to the ‘Pap scandal’ article published in the Wall Street Journal in 1987 and reports in The Lancet,4 efforts have been undertaken to improve the quality of cytological test results.. Thus, various new reporting systems and technologies such as the Bethesda system, implementation of screening programs, LBC, and human papilloma virus DNA (HPV DNA) detection methods, and automated cytology devices have been developed.5–11 These new technologies have brought stability and development to gynaecological cytology (GYN), making it an essential part of modern healthcare.12,13 Since LBC was first approved by the US Food and Drug Administration (US FDA) in 1996,14 widespread adoption in Western countries of GYNLBC resulted in the replacement of the conventional preparation (CP) method, reducing the specimen inadequacy rates and number of cases that were unsatisfactory for diagnosis.14–19 Subsequently, global studies on endometrial cytology have also used LBC as a replacement for the CP.20–25 In nongynaecological (fineneedle aspiration and exfoliative) cytology, all materials are placed on slides as airdried direct spreads and fixed direct spreads, and CP has been well established during the last few decades as the diagnostic test of choice for making initial diagnosis.. Similarly, the LBC method in diagnostic cytology (nongynaecological cytology) has been applied to and researched. Article Title: Cervical cancer screening efficacy using SurePath, ThinPrep and conventional cytology: A large data set analysis from the Japan Cancer Society. Article Snippet: Moreover, there was a disparity between the number of cases using LBC and conventional method.9 There are two major LBC platforms, |